Loading clinical trials...
Loading clinical trials...
The pupose of this study is to evaluate the safety and the efficacy of ranibizumab in rare VEGF driven ocular diseases.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis Pharmaceuticals
NCT07425522 · Diabetic Macular Edema
NCT07440225 · Macular Degeneration, Age-Related Macular Degeneration, and more
NCT07308639 · Neovascular Age-related Macular Degeneration (nAMD); Diabetic Macular Edema (DME); Retinal Vein Occlusion (RVO)
NCT07520045 · Diabetic Retinopathy (DR), Diabetic Macular Edema (DME)
NCT07449936 · Diabetic Macular Edema, DME, and more
Novartis Investigative Site
Bobigny, Seine Saint Denis
Novartis Investigative Site
Amiens
Novartis Investigative Site
Angers
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions